Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
The MiniMed™ 780G system (780G) received Conformité Européenne mark in June 2020 and was, recently, approved by the U.S. Food and Drug Administration (April 2023). Clinical trials and real-world analyses have demonstrated MiniMed™ 780G system safety and effectiveness and that glycemic outcomes (i.e., time in range) improve with use. In this publication, we will explain the iterative development of the 780G algorithm and how this technology has simplified diabetes management.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1089/dia.2023.0446 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Hypoglycemia incidence and behavioural adjustments during free-living unstructured physical activity in adults with type 1 diabetes using AID systems: Results from the RAPPID study.
Diabetes Obes Metab
September 2025
Diabetes Care Unit, Nancy University Hospital, Nancy, France.
Aims: To assess the frequency and management of hypoglycaemia during unstructured physical activity (PA) in adults with type 1 diabetes (T1D) using automated insulin delivery (AID) systems in real-life settings.
Materials And Methods: RAPPID is a prospective, multicenter, observational study conducted over 1 month in four French tertiary care centres. Adults with T1D using one of three AID systems (MiniMed 780G, Tandem t:slim X2 with Control-IQ, or Ypsopump with CamAPS FX) and performing ≥2 unstructured PA sessions per week were included.
[Advanced Hybrid Closed Loop (AHCL) System for Glucose Monitoring and Automatic Insulin Microinfusion in Dialysis].
G Ital Nefrol
August 2025
Infermiere Professionale SSD Nefrologia e Dialisi P.O. Soverato, ASP CZ.
Management of diabetes mellitus in hemodialysis is highly complex due to increased glycemic variability and hypoglycemic risk. The use of technologies applied to diabetes has been shown to improve glycemic control, however data in dialysis patients are limited. To describe the efficacy and safety of the minimed 780G AHCL system in a stable hemodialysis patient and during hospitalization in the Intensive Care Unit (ICU).
View Article and Find Full Text PDFOnset of Addison Disease in a Patient Using the Advanced Hybrid Closed-Loop MiniMed 780G: Diagnostic Challenges.
JCEM Case Rep
October 2025
Servicio de Endocrinología y Nutrición, Hospital Universitario Clínico San Carlos, Madrid 28040, Spain.
This case report describes a 25-year-old woman with type 1 diabetes mellitus (T1DM) and autoimmune thyroid disease (AITD) who developed Addison disease (AD). The diagnosis was suspected due to a significant decrease in insulin requirement and recurrent hypoglycemia despite adjustments in insulin pump therapy. The patient exhibited typical clinical features of AD, including hyperpigmentation and electrolyte imbalances.
View Article and Find Full Text PDFImpact of tailored diabetes education on adherence and glycemic control in children and adolescents on continuous subcutaneous insulin infusion, prospective interventional study in a tertiary center.
BMC Pediatr
September 2025
Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt.
Background: Structured diabetes education plays a crucial role in the management of Type 1 Diabetes (T1D), especially with advanced technologies such as continuous subcutaneous insulin infusion (CSII). This study evaluates the impact of tailored education on adherence and glycemic control among pediatric CSII users.
Patients And Methods: This interventional analytical study included 30 patients diagnosed with T1D with age ranged from 5 to 18 years, recruited from Diabetes & Endocrinology Clinic at tertiary university-based children's hospital.
Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor.
Diabetes Technol Ther
August 2025
Medtronic, Northridge, California, USA.
The present study assessed the impact of the disposable Simplera Sync™ sensor with the MiniMed™ 780G (MM780G) advanced hybrid closed-loop (AHCL) system on type 1 diabetes (T1D) glycemic metrics, insulin delivery, and safety. Youths (aged 7-17 years) and adults (aged 18-80 years) with T1D were enrolled in this single-arm, nonrandomized study at 24 sites in the United States. Participants began with an ∼2-week run-in period where hybrid closed-loop (HCL; auto basal only) or open-loop insulin delivery was used, followed by an ∼3-month study period with AHCL activated.
View Article and Find Full Text PDF